EOM Pharmaceuticals Holdings, Inc. (IMUC)

Market Cap	26.60M +76.7%
Revenue (ttm)	n/a
Net Income	-5.13M
EPS	-0.05
Shares Out	126.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	0.2500
Previous Close	0.2520
Day's Range	0.2500 - 0.2700
52-Week Range	0.0360 - 0.3399
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About IMUC

EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company’s lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects that has completed Phase 2 clinical trials for the treatment of cancer cachexia, AIDS/cancer cachexia, HIV/AIDS, and rheumatoid arthritis, as...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: IMUC

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 18, 2026

Data Sources Report a data error